1. Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger?

    Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger?

    After Bristol-Myers Squibb and activist investor Starboard Value released dueling presentations on the planned $74 billion merger with Celgene earlier this week, Wall Street analysts started speculating about what might actually cause the deal to go south...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Topics Mentioned